News Releases

Date Title and Summary Additional Formats
Toggle Summary Sarepta Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
CAMBRIDGE, Mass. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the Morgan Stanley 17 th Annual Global Healthcare Conference on Monday, September 9,
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Aug. 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on August 30, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s
View HTML
Toggle Summary Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application
CAMBRIDGE, Mass. , Aug. 19, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration ( FDA ) regarding the New Drug
View HTML
Toggle Summary Sarepta Therapeutics Comments on Erroneous Submission to US FDA Adverse Event Reporting System (FAERS)
CAMBRIDGE, Mass. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, was informed earlier today that an adverse event report was erroneously submitted to the FDA’s adverse event reporting system (FAERs), a
View HTML
Toggle Summary Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2019. “As we pass through mid-2019, we are very pleased to announce strong
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , July 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 31, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s
View HTML
Toggle Summary Sarepta Therapeutics to Announce Second Quarter 2019 Financial Results and Recent Corporate Developments on August 7, 2019
CAMBRIDGE, Mass. , July 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2019 financial results after the Nasdaq Global Market closes on Wednesday, August 7, 2019 .
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , June 28, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 28, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s
View HTML
Toggle Summary Sarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
CAMBRIDGE, Mass. , June 04, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the Goldman Sachs 40 th Annual Global Healthcare Conference on Tuesday, June 11, 2019 at
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , May 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.

There are no items to display.